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planning systems: Varian's Eclipse for extracranial treatments 
and with Brainlab's iplan for intracranial treatments. 
Results: Output factors of 1000 SRS agreed with semiflex 
measurements for field size between 3x3cm² and 10x10 cm². 
The larger deviations were observed for the 1x1 cm² field 
size: compared to microDiamond, deviations of 1.6%, 2.5%, 
1.7% and 3.3% were observed for 6, 10 MV FF and 6, 10 MV 
FFF respectively. For the 2x2 cm² field size, deviations were 
less than 1.5% for 6 MV FF and 6 MV FFF and 2.5% for 10 MV 
FF and 10 MV FFF. The 1000 SRS showed large dependent 
dose rate response. This effect was about 1% for 6, 10 MV FF 
and increased to 2.5% for 6 MV FFF and 4% for 10 MV FFF. 
Stereotactic treatment plans gave excellent agreement with 
more than 95% of pixels passing 2%/2mm gamma criteria.  
 
Conclusions: The 4D octavius phantom with associated 1000 
SRS ionization chamber array could be used for stereotactic 
pretreatment QA of FF and FFF beams. It is however 
mandatory to calibrate 1000 SRS for a field size and a dose 
rate close to the patient treatment plan. 
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Purpose/Objective: When ArcCHECK (Sun Nuclear Corp., 
Melbourne, FL) is used for Quality Assurance (QA) on helical 
Tomotherapy treatment plans, Tomotherapy measurement 
mode is applied and there is no correction on diode response 
for field size dependency. It is recommended to use a 
standard size 40x5 cm2 of Tomotherapy static beam for 
ArcCHECK absolute dose calibration . Under such dose 
calibration ArcCHECK measurement does not produce good 
result for helical treatment plan with small target (dimension 
< 3 cm) and high modulation factor (>2.5), with gamma 
passing rate (3% dose, 3 mm distance to agreement) normally 
below 85% in absolute dose comparison. During such helical 
treatment, there are fast and frequent movement of small 
number of MLC leaves while the gantry is rotating. It is 
similar to small field irradiation at many different gantry 
angles. Solid state diodes on the ArcCHECK are slightly 
energy dependent and more sensitive to low energy 
component of the treatment beam. As the energy spectrum 
of treatment beam changes for small field size, the 
sensitivity of the diodes changes correspondingly. In this work 
the ArcCHECK measurements were done on 10 helical 
Tomotherapy treatment plans with small target and high 
modulation factor, with ArcCHECK calibrated under standard 
field (40x5 cm2) and small field (2x2cm2) treatment beam 
respectively to demonstrate if it is necessary to do small field 
dose calibration on ArcCHECK for such Tomotherapy 
treatment QA. 
Materials and Methods; 10 helical Tomotherapy treatment 
plans, with small target size (dimension < 3cm) and high 
modulation factor (>2.5), were used in the study. ArcCHECK 
absolute dose calibration was done initially with a standard 
field (40x5 cm2) and 0.057 cc ionization chamber (A1SL, 
Standard Imaging Inc, Middleton, WI). Absolute point dose 
measurements were also done by placing A1SL ionization 
chamber at the centre of the ArcCHECK with PMMA insert. 
After ArcCHECK measurement on these 10 helical treatment 
plans, absolute dose comparisons between the measurement 
and planning calculation were carried out with gamma test 
(3% dose, 3 mm). The measurements were repeated with 
ArcCHECK calibrated under small field 2x2cm2. The 
difference between the responses of the chamber in the 
standard field and small field 2x2cm2 was corrected in small 
field calibration. 
Results: Absolute point dose measurements for all plans 
showed good agreement with planning calculation as the 
differences were all within ± 2%. When standard field size 
(40x5 cm2) calibration was used, the gamma passing rate of 
ArcCHECK measurements were below 85% (Mean=79.5%, 
S.D.=3.3%) for all plans. When small field (2x2cm2) dose 
calibration was used instead, the gamma passing rates for all 
plans were over 90% (Mean=93.7%, S.D.=1.8%). 
Conclusions: Sensitivity of the diode changes for small 
irradiation field. Small field (2x2cm2) dose calibration on 
ArcCHECK should be used instead when measuring helical 
Tomotherapy treatment with small target and high 
modulation factor in order to correct such sensitivity change.  
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Purpose/Objective: Stereotactic radiation therapy 
(SRS/SBRT) require a more comprehensive quality assurance 
(QA) program than 3DCRT and IMRT (or VMAT), especially 
because of its very high-dose gradients. The purpose of this 
study is to test a IBA 3D dosimetry analysis package, COMPASS 
3.0 with MatriXXEvolution ion chamber array, for SRS/SBRT pre-
treatment verification in terms of 3D dose, gamma analysis, 
Target and OAR structures DVH. 
Materials and Methods: Nine treatment plans (SRS/SBRT) 
with different dose fractionations have been selected: 3 
brain cases (2 cases of 21Gy x 1 and one of 15Gy x 1), 3 liver 
cases (15Gy x 3) and 3 lung cases (2 cases of 15 Gy x 3 and 
one of 8 Gy x 4). All measurements, performed with 
COMPASS, were compared with the reference dose 
